Latest Conference

Compared with no pharmacist involvement, a greater number of appropriate antiretroviral regimens were initiated with partial pharmacist involvement (62% vs. 32%, p = 0.0096).

Contagion® will be heading to Orlando, Florida, on Wednesday, May 8, 2019, to report on the annual Making a Difference in Infectious Diseases (MAD-ID) 2019 conference.

Steven Tong, PhD, discusses the next steps for research on combination therapy for MRSA bacteremia.

Experts from the fields of microbiology and infectious disease share their biggest takeaways and highlights from ECCMID 2019.

Nicole Cotroneo, BS, discusses her research presented at ECCMID 2019 on the activity of tebipenem against multidrug-resistant urinary tract infection-causing pathogens.

Ben Berkhout, MD, PhD, discusses his work on the development of a novel curative strategy for HIV-1 infected individuals.

Experts from the fields of microbiology and infectious disease share their biggest takeaways and highlights from ECCMID 2019.

An intervention involving improved communication and antibiotic timeouts in nursing homes reduced the days of antibiotic therapy, according to a recent study.

Elizabeth Hirsch, PharmD, and Mélanie Mahoney, PharmD candidate, discuss their poster on Escherichia coli ST131 in Boston vs Minneapolis at ECCMID 2019.

The aggregated average HAI rates before and after discontinuing contact precautions were 0.14 and 0.15 MRSA HAI/1000 patient days, 0.06 and 0.04 VRE HAI/1000 patient days, and 0.04 and 0.03 MRSA LabID events/100 admissions.

The rate of health care-associated influenza cases per season decreased from a median of 16.8 cases pre-policy rollout to 5.2 cases post-policy rollout at a large pediatric hospital.

Marin Kollef, MD, discusses recently approved agents targeting antibiotic resistant gram-negative bacteria and what to expect in the next 5 years.

Non-sporicidal cleansers are commonly used to disinfect surfaces in the hospital rooms of patients with C auris colonization or infection, but are they efficacious?

Investigators in New York state, which has the largest burden of C auris colonization in the US, used 12 point prevalence surveys at 6 nursing homes to identify 60 cases and 218 controls.

In a South Korean study of contaminated stethoscopes, 23% were confirmed to have at least 1 potential multidrug-resistant bacterial pathogen.

Corrine Maurice, PhD, discusses her talk at the European Congress of Clinical Microbiology and Infectious Disease (ECCMID 2019) on the interactions between host, bacteria, gut microbiota, and bacteriophages.

Ben Berkhout, PhD, discusses if CRISPR/Cas9 will be a new antiviral strategy for the eradication of HIV.

Here are the top takeaways from the European Congress of Clinical Microbiology and Infectious Disease 2019 meeting.

At ECCMID 2019, László Majoros, MD, PhD, spoke about rezafungin’s activity against common and rare Candida species in vitro.

Tristan Ferry, MD, PhD, discusses why there is a need to develop alternatives to treat chronic bone and joint infections.

Madeline King, PharmD, discusses her research presented at ECCMID 2019 on pre-operative asymptomatic bacteriuria and appropriateness of aztreonam usage.

Laura Shallcross, PhD, discusses how clinicians have “a low threshold” for initiating antibiotics in the emergency department for patients with symptoms similar to a UTI.

Leslie Tari, PhD, discusses Cidara Therapeutics' Cloudbreak antiviral initiatives.

A study using monkeys provides an intriguing glimpse of the possibilities of using CRISPR gene editing technology to knock out HIV reserves in humans.

Will biomarker-guided specific therapies the best option for treating sepsis in the future?

During a year-long study, 80 electronic conversational comments were made using the stewardship team’s audit-and-feedback tool and recommendations were fully adopted 90% of the time.

Oral ibrexafungerp demonstrates a favorable therapeutic response in patients with difficult-to-treat Candida infections, including those caused by non-albicans Candida species.

Lefamulin demonstrated non-inferiority when compared with moxifloxacin, and both treatment arms reported a low rate of serious treatment-emergent AEs or treatment-emergent AEs leading to discontinuation.

Cidara Therapeutics has developed CB-012, a stable conjugate of a highly potent antiviral agent linked to human IgG1 Fc, and investigators are evaluating the asset for the treatment and prevention of seasonal and pandemic influenza A and B infections.

The ASPECT-NP trial compared a new 3-gram dose regimen of ceftolozane/tazobactam versus meropenem in the treatment of ventilated nosocomial pneumonia.